Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Loxo Oncology Initiates Rolling Submission of NDA to FDA for Larotrectinib for the Treatment of TRK

biospaceDecember 21, 2017

Tag: Loxo , FDA , Larotrectinib

PharmaSources Customer Service